Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;96(4):470-6.
doi: 10.1038/clpt.2014.121. Epub 2014 Jun 4.

Phenotype standardization for statin-induced myotoxicity

A Alfirevic  1 , D Neely  2 , J Armitage  3 , H Chinoy  4 , R G Cooper  5 , R Laaksonen  6 , D F Carr  1 , K M Bloch  1 , J Fahy  1 , A Hanson  1 , Q-Y Yue  7 , M Wadelius  8 , A H Maitland-van Der Zee  9 , D Voora  10 , B M Psaty  11 , C N A Palmer  12 , M Pirmohamed  1
Affiliations

Phenotype standardization for statin-induced myotoxicity

A Alfirevic et al. Clin Pharmacol Ther. 2014 Oct.

Abstract

Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Algorithm for defining the type of statin-related myotoxicity. New nomenclature was introduced to reflect the phenotype classification and severity (SRM 0 to SRM 6) of statin-related toxicity. CK, creatine kinase; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LLD, lipid-lowering drug; SRM, statin-related myotoxicity; ULN, upper limit of normal.
See this image and copyright information in PMC

References

    1. Law M., Rudnicka A.R. Statin safety: a systematic review. Am. J. Cardiol. 2006;97:52C–60C. - PubMed
    1. Sathasivam S. Statin induced myotoxicity. Eur. J. Intern. Med. 2012;23:317–324. - PubMed
    1. Stone N.J., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013. e-pub ahead of print 12 November 2013. - PubMed
    1. Graham D.J., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–2590. - PubMed
    1. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002;346:539–540. - PubMed

Publication types

MeSH terms

Substances